Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
4
100%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Terminated(1)
Other(1)

Detailed Status

Completed2
Withdrawn1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

withdrawn125%
completed250%
unknown125%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_1

Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia

NCT03441048
unknownphase_1

Venetoclax and Lintuzumab-Ac225 in AML Patients

NCT03867682
completedphase_1

Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients

NCT02575963
withdrawnphase_1

Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients

NCT03932318

Clinical Trials (4)

Showing 4 of 4 trials
NCT03441048Phase 1

Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid Leukemia

Completed
NCT03867682Phase 1

Venetoclax and Lintuzumab-Ac225 in AML Patients

Unknown
NCT02575963Phase 1

Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients

Completed
NCT03932318Phase 1

Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4